Pharmaxis progresses Bronchitol

By Kate McDonald
Tuesday, 05 May, 2009

Pharmaxis has reported positive results from its Phase III trial of lead candidate Bronchitol in cystic fibrosis patients.

Bronchitol, a dry-powder mannitol formulation that hydrates the airway surface of the lungs and helps clear mucus build-up, was found to improve lung function significantly when administered twice a day for six months.

It also improved lung function when used in conjunction with dornase alfa (Pulmozyme), the most commonly used cystic fibrosis drug.

The trial was conducted in 40 centres in Europe, Australia and New Zealand in consultation with the European Medicines Agency. Pharmaxis hopes to gain marketing authorization in Europe and will file an application later this year.

It has already received orphan drug designation and fast track status from the US FDA.

The company said it would present the study’s findings at a European scientific meeting in June and an American scientific meeting in October.

Related News

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd